Light-chain (AL) amyloidosis - historical
Revision as of 11:46, 15 July 2024 by Warner-admin (talk | contribs) (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed'''")
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? Please go to the main light-chain (AL) amyloidosis regimen page to find other regimens.
2 regimens on this page
2 variants on this page
|
First-line therapy (including transplant ineligible)
Colchicine monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kyle et al. 1985 | Not reported | Randomized (E-switch-ooc) | MP | Did not meet primary endpoint of OS |
Cohen et al. 1987 | 1976-1983 | Non-randomized | ||
Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. MP | Inferior OS |
2. Melphalan, Prednisone, Colchicine | Inferior OS |
References
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
- Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. link to original article PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article dosing details in manuscript have been reviewed PubMed
Melphalan & Prednisone (MP)
MP: Melphalan & Prednisone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kyle et al. 1978 | Not reported | Randomized (E-esc) | Placebo | Longer time on treatment |
Kyle et al. 1985 | Not reported | Randomized (E-switch-ooc) | Colchicine | Did not meet primary endpoint of OS |
Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. Colchicine | Superior OS |
2. Melphalan, Prednisone, Colchicine | Did not meet primary endpoint of OS |
Note: some studied divided the doses of melphalan and prednisone; others did not; see individual papers for details.
Chemotherapy
- Melphalan (Alkeran) 0.15 mg/kg/day PO on days 1 to 7
Glucocorticoid therapy
- Prednisone (Sterapred) 0.8 mg/kg/day PO on days 1 to 7
42-day cycles
References
- Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. link to original article dosing details in manuscript have been reviewed PubMed
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article dosing details in manuscript have been reviewed PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article dosing details in manuscript have been reviewed PubMed